<DOC>
	<DOCNO>NCT00091689</DOCNO>
	<brief_summary>Study 1501-852A Phase 1 Study objective determine safety high tolerate dose immune response modifier cream directly apply advanced , inoperable , melanoma skin lesion . The study also measure blood level drug examine potential anti-tumor activity cream .</brief_summary>
	<brief_title>Safety Efficacy Immune Response Modifier Treat Inoperable Advanced Melanoma Skin Lesions</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Have melanoma cutaneous metastasis lentigo maligna melanoma unresectable standard curative palliative measure exist longer effective . Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 Have life expectancy 4 month Have normal organ bone marrow function Need nonsteroidal antiinflammatory drug ( NSAIDs ) study Have body mass index ( BMI ) &gt; 30 kg/m2 Have history , clinical evidence , myocardial ischemia , congestive heart failure , myocardial arrhythmia require treatment within past 6 month Have uncontrolled intercurrent chronic illness , limited , ongoing active infection hepatitis B C , immune dysfunction autoimmune disease , endocrine dysfunction hypo hyperthyroidism , psychiatric illness depression suicidal tendency social situation would limit compliance study requirement Have history disease require ongoing steroid treatment Have history seizure disorder ( febrile seizure childhood ) Have history clinically significant coagulation bleed disorder abnormality Are HIV positive . HIV positive subject exclude study possible interaction immunomodulatory effect 852A potential pharmacokinetic interaction associate combination retroviral therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Advanced Metastatic Melanoma</keyword>
</DOC>